Last reviewed · How we verify
Sulijia
Sulijia is a Small molecule drug developed by Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.. It is currently in Phase 3 development. Also known as: Recombinant endostatin injection.
Sulijia is a medication used to treat Advanced Non-small Cell Lung Cancer. It is administered in combination with other treatments, specifically vinorelbine and cisplatin, as part of a clinical trial.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Sulijia |
|---|---|
| Also known as | Recombinant endostatin injection |
| Sponsor | Jiangsu Wuzhong Pharmaceutical Group Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sulijia CI brief — competitive landscape report
- Sulijia updates RSS · CI watch RSS
- Jiangsu Wuzhong Pharmaceutical Group Co., Ltd. portfolio CI
Frequently asked questions about Sulijia
What is Sulijia?
Who makes Sulijia?
Is Sulijia also known as anything else?
What development phase is Sulijia in?
Related
- Manufacturer: Jiangsu Wuzhong Pharmaceutical Group Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Recombinant endostatin injection
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing